The nuclear factor kappa B signaling pathway: Integrating metabolism with inflammation

Trends in Cell Biology

Volumn 22, Issue 11, 2012, Pages 557-566

  Tornatore, Laura ^a   Thotakura, Anil K ^a   Bennett, Jason ^a   Moretti, Marta ^a   Franzoso, Guido ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Glycolysis; Metabolism; Mitochondria; NF B; Respiration

Indexed keywords

I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LONIDAMINE; PROTEASOME INHIBITOR;

AEROBIC METABOLISM; AGING; BIOENERGY; BREATHING; CARCINOGENESIS; COEVOLUTION; GLYCOLYSIS; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84867867477     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2012.08.001     Document Type: Review

References (84)

1. Di Donato J.A., et al. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246:379-400.
2. Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12:121-132.
3. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
4. Hayden M.S., Ghosh S. Shared principles in NF-κB signaling. Cell 2008, 132:344-362.
5. Baker R.G., et al. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011, 5:11-22.
6. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 2008, 8:923-934.
7. Solinas G., Karin M. JNK1 and IKKβ: molecular links between obesity and metabolic dysfunction. FASEB J. 2010, 24:2596-2611.
8. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
9. Barton G.M. A calculated response: control of inflammation by the innate immune system. J. Clin. Invest. 2008, 118:413-420.
10. Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007, 19:24-32.
11. Lago R., et al. Leptin beyond body weight regulation - current concepts concerning its role in immune function and inflammation. Cell. Immunol. 2008, 252:139-145.
12. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
13. Karagiannides I., Pothoulakis C. Obesity, innate immunity and gut inflammation. Curr. Opin. Gastroenterol. 2007, 23:661-666.
14. Vijay-Kumar M., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-Like Receptor 5. Science 2010, 328:228-231.
15. Schenk S., et al. Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 2008, 118:2992-3002.
16. Xu H., et al. Chronic inflammation in fat plays a crucial role in development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1839.
17. Rocha V.Z., Libby P. Obesity, inflammation and atherosclerosis. Nat. Rev. Cardiol. 2009, 6:399-409.
18. Iyer A., et al. Inflammatory lipid mediators in adipocyte function and obesity. Nat. Rev. Endocrinol. 2010, 6:71-82.
19. Horng T., Hotamisligil G.S. Linking the inflammasome to obesity-related disease. Nat. Med. 2011, 17:164-165.
20. Lumeng C.N., et al. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007, 56:16-23.
21. Wunderlich F.T., et al. Inrleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010, 12:237-249.
22. Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKKβ and NF-κB. Nat. Med. 2005, 11:183-190.
23. Arkan M., et al. IKKβ links inflammation to obesity-induced insulin resistance. Nat. Med. 2005, 11:191-198.
24. Gao Z., et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor of βB kinase complex. J. Biol. Chem. 2002, 277:48115-48121.
25. Herschkovitz A., et al. Common inhibitory serine sites phosphorylated by IRS-1 kinase, triggered by insulin and inducers of insulin resistance. J. Biol. Chem. 2007, 282:18018-18027.
26. Aguirre V., et al. The c-Jun NH(2)- terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 2000, 275:9047-9054.
27. Sharfi H., Eldar-Finkelman H. Sequential phosphorylation of insulin receptor substrate-2 by glycogen synthase kinase-3 and c-Jun NH2-terminal kinase plays a role in hepatic insulin signaling. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E307-E315.
28. Sabio G., et al. Role of muscle JNK1 in obesity-induced insulin resistance. Mol. Cell. Biol. 2010, 30:106-115.
29. Hirosumi J., et al. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
30. Solinas G., et al. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin receptor substrates. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16454-16459.
31. Prentky M., Nolan C. Islet β cell function in type 2 diabetes. J. Clin. Invest. 2006, 116:1802-1812.
32. Kim K.A., Lee M.S. Recent progress in research on β-cell apoptosis by cytokines. Front. Biosci. 2009, 14:657-664.
33. Zhang X., et al. Hypothalamic IKKβ/NF-κB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008, 135:61-73.
34. Ozcan L., et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009, 9:35-51.
35. Tenoever B.R., et al. Multiple functions of the IKK-related kinase IKKe{open} in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278.
36. Chiang S.H., et al. The protein kinase IKKe{open} regulates energy balance in obese mice. Cell 2009, 138:961-975.
37. Mauro C., et al. NF-κB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat. Cell Biol. 2011, 13:1272-1279.
38. Kawauchi K., et al. p53 regulates glucose metabolism through an IKK- NF-κB pathway and inhibits cell transformation. Nat. Cell Biol. 2008, 10:611-618.
39. Johnson R.F., et al. p53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-κB. Cancer Res. 2011, 71:5588-5597.
40. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
41. Vander Heiden M.G., et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2008, 324:1029-1033.
42. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Ann. N. Y. Acad. Sci. 2009, 1177:66-73.
43. Hanson J.L., et al. The nuclear factor κB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res. 2004, 64:7248-7255.
44. Kawauchi K., et al. Loss of p53 enhances catalytic activity of IKKβ through O-linked beta-N-acetyl glucosamine modification. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3431-3436.
45. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
46. Muller P.A., et al. p53 and its mutants in tumour cell migration and invasion. J. Cell Biol. 2011, 192:209-218.
47. Vousden K.H., Ryan K.M. p53 and metabolism. Nat. Rev. Cancer 2009, 9:691-700.
48. Jones R.G., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18:283-293.
49. Leary S.C. Redox regulation of SCO protein function: controlling copper at a mitochondrial crossroad. Antioxid. Redox Signal. 2010, 13:1403-1416.
50. Matoba S., et al. p53 regulates mitochondrial respiration. Science 2006, 16:1650-1653.
51. Meylan E., et al. Requirement for NF-κB signaling in a mouse model of lung adenocarcinoma. Nature 2009, 462:104-107.
52. Mayo M.W. Ras regulation of NF-κB and apoptosis. Methods Enzymol. 2001, 333:73-87.
53. Luo J.L., et al. Inhibition of NF-κB in cancer cells converts inflammation-induced tumour growth mediated by TNF-α to TRAIL-mediated tumour regression. Cancer Cell 2004, 6:297-305.
54. Greten F.R., et al. IKK-β links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
55. Dajee M., et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003, 421:639-643.
56. Gapuzan M.E., et al. Immortalized fibroblasts from NF-κB RelA knockout mice show phenotypic heterogeneity and maintain increased sensitivity to tumor necrosis factor α after transformation by v-Ras. Oncogene 2005, 24:6574-6583.
57. Locasale J.W., et al. Cancer's insatiable appetite. Nat. Biotechnol. 2009, 27:916-917.
58. Buzzai M., et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007, 67:6745-6752.
59. Hockenbery D.M. Targeting mitochondria for cancer therapy. Environ. Mol. Mutagen. 2010, 51:476-489.
60. Weinberg F., et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:8788-8793.
61. Guo J.Y., et al. Activated Ras requires autophagy. Genes Dev. 2011, 25:460-470.
62. Vousden K.H. Alternative fuel - another role for p53 in the regulation of metabolism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7117-7118.
63. Kaul S.C., et al. Three faces of mortalin: a housekeeper, guardian and killer. Exp. Gerontol. 2007, 42:263-274.
64. Yaguchi T., et al. Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative stress management functions. Ann. N. Y. Acad. Sci. 2007, 1100:306-311.
65. Schneider G., et al. Cross talk between stimulated NF-κB and the tumor suppressor p53. Oncogene 2010, 29:2795-2806.
66. Koppenol W.H., et al. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 2011, 11:325-337.
67. Baud V., Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
68. Laubach J.P., et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009, 23:2222-2232.
69. McConkey D.J., Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist. Updat. 2008, 11:164-179.
70. Nencioni A., et al. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007, 21:30-36.
71. Greten F.R., et al. NF-κB is a negative regulator of IL-1β secretion as revealed by genetic and pharmacological inhibition of IKKβ. Cell 2007, 130:918-931.
72. Jose C., et al. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma?. Biochim. Biophys. Acta 2011, 1807:552-561.
73. Hockenbery D.M. Targeting mitochondria for cancer therapy. Environ. Mol. Mutagen. 2010, 51:476-489.
74. Pelicano H. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
75. Rodríguez-Enríquez S., et al. Targeting of cancer energy metabolism. Mol. Nutr. Food Res. 2009, 53:29-48.
76. Nomura D.K., et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
77. Semenza G.L. Regulation of vascularization by hypoxia-inducible factor 1. Ann. N. Y. Acad. Sci. 2009, 1177:2-8.
78. Keit B., et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.
79. Frezza C., Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Semin. Cancer Biol. 2009, 19:4-11.
80. Taylor C.T. Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J. Physiol. 2008, 586:4055-4059.
81. Lum J.J., et al. The transcription factor HIF-1α plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007, 21:1037-1049.
82. Deberardinis R.J., et al. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 2008, 18:54-61.
83. Menendez J.A., et al. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
84. Tergaonkar V., Perkins N.D. p53 and NF-κB crosstalk: IKKα tips the balance. Mol. Cell 2007, 26:158-159.